After more than a decade of global consultation, polycystic ovary syndrome (PCOS) has been officially renamed. The condition, which affects up to one in eight women, is now known as polyendocrine metabolic ovarian syndrome (PMOS). This change comes after extensive advocacy from campaigners who argued that the original name did not accurately reflect the condition's complexity and metabolic implications.
Why the Name Change?
PCOS is caused by high levels of androgens, leading to symptoms such as excess hair growth, weight gain, and irregular periods. However, the condition also involves significant metabolic and endocrine components. Campaigners, including Rachel from the charity Verity, pushed for a name that better represents the full spectrum of symptoms and underlying mechanisms. The new name, PMOS, highlights the polyendocrine and metabolic aspects, potentially leading to better diagnosis and treatment.
What PMOS Means for Patients
The renaming is expected to bring fresh hope to millions of women worldwide. By emphasising the metabolic and endocrine nature of the condition, healthcare providers may adopt a more holistic approach to treatment. This could include earlier interventions for related issues such as insulin resistance and cardiovascular risk, which are common in women with PMOS. The Guardian's science correspondent, Nicola Davis, notes that the change is the result of an 'unprecedented' global effort involving experts and patient advocates.
Rachel, a campaigner from Verity, expressed optimism: 'This new name gives us a better understanding of the condition and may reduce stigma. It acknowledges that PMOS is not just about ovaries, but a whole-body disorder.'
For women living with the condition, the rename could improve awareness and encourage more research into targeted therapies. The shift from PCOS to PMOS represents a significant step forward in women's health, offering a more accurate framework for diagnosis and management.
